ADRC News

The AHEAD Study is a new research study examining whether intervening ahead of symptoms may prevent future memory loss and dementia. AHEAD is the first research study that aims to help prevent Alzheimer’s disease by enrolling participants as young as 55 and using a tailored dosing approach.

The study looks at an investigational treatment aimed at delaying memory decline in people up to 20 years before the symptoms of Alzheimer’s disease appear. Discovering a treatment...

In a special segment during the recent “Healthy Living with Mild Cognitive Impairment (MCI): Nutrition in Action,” Nathaniel Chin, MD, and Michelle Braun, PhD, a neuropsychologist and national leader in the field of brain health, discussed the U.S. Food and Drug Administration's recent approval of the drug aducanumab, marketed as Aduhelm, for the treatment of Alzheimer's disease. They explained how the drug works to reduce amyloid in the brain, concerns around the treatment, and next...

On June 7, the U.S. Food and Drug Administration (FDA) approved the drug aducanumab for the treatment of Alzheimer’s disease. It is the first new treatment approved for Alzheimer’s disease since 2003

Tobey Betthauser, PhD, was recently elected to the executive committee of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) Neuroimaging Professional Interest Area (PIA). Betthauser's new role as Steering Committee Member/Junior Scientist will begin after the 2021 Alzheimer's Association International Conference, slated for July 26-30 in Denver, Colorado.

The Neuroimaging PIA works to address the clinical application and methodological development of neuroimaging (MRI, PET, SPECT, CT, and others) to Alzheimer's...

The University of Wisconsin School of Medicine and Public Health launched the UW Center for Health Disparities Research in April 2021. The new center seeks to examine how a person’s environment and social conditions impact their health down to the molecular level.

The Wisconsin Alzheimer's Disease Research Center will host the inaugural Dr. Daniel I. Kaufer Lecture on June 1, 4–5:15 p.m. on Zoom. Guest lecturer Bradley F. Boeve, MD, Mayo Clinic, will present "Diagnosis and Management of Dementia with Lewy Bodies." 

African American leaders from local churches, civic organizations, academia and health groups are lending their insight — their lived experience — to UW Alzheimer’s disease research. The committee, Black Leaders for Brain Health, is a collaboration between the Nehemiah Center for Urban Leadership Development and the Wisconsin Alzheimer’s Disease Research Center (ADRC)

Gina Green-Harris, Dr. Carey Gleason and Dr. Shenikqua Bouges join episodes of "Super Aging," a new podcast hosted by Fatou Ceesay, owner of Cairasu Home Care in Madison, Wisconsin.

A new study from the Puglielli Lab opens a door to potential treatments for diseases of age, such as Alzheimer’s disease, by defining the roles of two enzymes that are imperative to protein production.

Researchers report finding a correlation between living in neighborhoods with the fewest social and economic advantages and experiencing changes in brain structure and function that are characteristic of Alzheimer’s disease and related dementias.